Holen Sie sich die Stockscreener-App
0.9498
6.72%
0.0598
Vorhandelsmarkt:
.95
0.0002
+0.02%
Schlusskurs vom Vortag:
$0.89
Offen:
$0.89
24-Stunden-Volumen:
212.91K
Relative Volume:
1.32
Marktkapitalisierung:
$34.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-1.6258
EPS:
-0.5842
Netto-Cashflow:
-
1W Leistung:
+17.42%
1M Leistung:
+14.43%
6M Leistung:
-9.43%
1J Leistung:
-11.23%
1-Tages-Spanne:
$0.89
$0.96
1-Wochen-Bereich:
$0.761
$0.96
52-Wochen-Spanne:
$0.63
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.9498 | 34.29M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
NeuroSense Announces Pricing of Insider-Led PIPE Financing - The Malaysian Reserve
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price - TipRanks
NeuroSense (Nasdaq: NRSN) insiders lead $600K PIPE financing at premium - Stock Titan
NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding - marketscreener.com
Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo
NeuroSense CEO, CFO and investor commit $600K at a premium - Stock Titan
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail
NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan
Niva Russek Blum Net Worth (2026) - GuruFocus
Ferenc Tracik Net Worth (2026) - GuruFocus
Hagit Binder Net Worth (2026) - GuruFocus
Alon Ben Noon Net Worth (2026) - GuruFocus
Revital Mandil Levin Net Worth (2026) - GuruFocus
Tangible book value per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EBIT per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Operating cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NEUROSENSE THERAPEUTICS LTD (NRSN) Earnings History & Surprises - ChartMill
Form 20-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)] - ADVFN
Sentiment Review: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Nasdaq Moves: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Patterns Watch: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETF2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan
Trend Report: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingWeekly Risk Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Bank Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingMarket Weekly Review & Daily Stock Trend Reports - baoquankhu1.vn
Chipmakers Recap: Why is NeuroSense Therapeutics Ltd stock going downEarnings Growth Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Aug Highlights: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectations2026 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
NRSN Analyst Rating Update: D. Boral Capital Maintains 'Buy' Rat - GuruFocus
Inflation Data: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowEarnings Summary Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leaders2026 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Breakout Watch: Is NeuroSense Therapeutics Ltd gaining market share2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Income Plays: Is NeuroSense Therapeutics Ltd stock a value trap2026 AllTime Highs & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd stock a buy or sellMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
NeuroSense granted Brazilian patent covering PrimeC composition - TipRanks
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - marketscreener.com
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC - TipRanks
NeuroSense Granted Brazilian Patent Covering PrimeC Composition - Bitget
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status - The Globe and Mail
NRSN PE Ratio & Valuation, Is NRSN Overvalued - Intellectia AI
NeuroSense Therapeutics Ltd. (NRSN) stock price, news, quote and history - Yahoo Finance UK
NeuroSense Therapeutics Receives Nasdaq Notifications on Compliance Issues - National Today
NeuroSense Faces Nasdaq Compliance Warning - Intellectia AI
Nasdaq flags NeuroSense (NRSN) for bid price and $35M value shortfall - Stock Titan
NeuroSense Therapeutics Ltd. Stock Forecast Summary - Meyka
NRSN’s $1.00 Bid Price Requirement Serves as Key Trigger for Meeting Compliance and Raising Capital - Bitget
NRSN SEC FilingsNeurosense Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NeuroSense (NRSN) CFO awarded 200,000 restricted shares vesting over 2 years - Stock Titan
NeuroSense (NRSN) CFO Or Eisenberg reports 573,126 shares and warrants on Form 3 - Stock Titan
Free cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial - TipRanks
NeuroSense Therapeutics (NRSN) director details options and restricted shares - Stock Titan
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):